GSK said in a statement that it is confident that it will be able to launch Arexvy in time for the 2023/24 RSV season, describing the new vaccine as a “turning point” in efforts to reduce the ...
evaluated newly approved RSV vaccines: Arexvy, manufactured by GSK, and Abrysvo, manufactured by Pfizer. The study did not include a third approved vaccine, Moderna's mRESVIA. The vaccines are ...
GSK’s Arexvy has become the first respiratory syncytial virus (RSV) vaccine to be approved by the European Commission (EC) for use in adults aged 50 to 59 years who are at an increased risk of ...